Special Issue

Selecting the Best Approach for Single and Multiple Liver Tumors

Message from the Guest Editors

Liver surgery is considered the cornerstone treatment for hepatocellular carcinoma and colorectal liver metastases. Since the first laparoscopic liver resection, its uptake has been slow. However, there is still a place for open liver resection, especially for some particular and challenging situations. Furthermore, there is the need for performing more complex procedures than for other pathologies, such as anatomical liver resections for HCC or parenchymal-sparing surgery for CRLM. It is important for all liver surgeons to know which is the best approach in these variable conditions. We are pleased to invite the submission of articles concerning the advantages and drawbacks of the different possible approaches for the aforementioned liver tumors, including anatomical and parenchymal-sparing hepatectomy, as well as open and minimally invasive approaches. The aim of this Special Issue is to provide a platform for all current evidence and knowledge relevant to selecting the best approaches for liver tumors when dealing with single or multiple HCC and CRLM.We look forward to receiving your contributions.

Guest Editors

Prof. Dr. Ho-Seong Han

Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si 13620, Korea

Dr. Gianluca Cassese

Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si 13620, Korea

Deadline for manuscript submissions

closed (15 April 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



mdpi.com/si/128297

Cancers MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 cancers@mdpi.com

mdpi.com/journal/

cancers







an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



cancers



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)